Literature DB >> 32544236

CD4+ T-cell killing of multiple myeloma cells is mediated by resident bone marrow macrophages.

Ole Audun W Haabeth1,2, Kjartan Hennig1, Marte Fauskanger1,3, Geir Åge Løset4, Bjarne Bogen1,5, Anders Tveita1,3.   

Abstract

CD4+ T cells may induce potent antitumor immune responses through interaction with antigen-presenting cells within the tumor microenvironment. Using a murine model of multiple myeloma, we demonstrated that adoptive transfer of idiotype-specific CD4+ T cells may elicit curative responses against established multifocal myeloma in bone marrow. This finding indicates that the myeloma bone marrow niche contains antigen-presenting cells that may be rendered tumoricidal. Given the complexity of the bone marrow microenvironment, the mechanistic basis of such immunotherapeutic responses is not known. Through a functional characterization of antitumor CD4+ T-cell responses within the bone marrow microenvironment, we found that killing of myeloma cells is orchestrated by a population of bone marrow-resident CD11b+F4/80+MHC-IIHigh macrophages that have taken up and present secreted myeloma protein. The present results demonstrate the potential of resident macrophages as powerful mediators of tumor killing within the bone marrow and provide a basis for novel therapeutic strategies against multiple myeloma and other malignancies that affect the bone marrow.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2020        PMID: 32544236      PMCID: PMC7322971          DOI: 10.1182/bloodadvances.2020001434

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  48 in total

1.  Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice.

Authors:  Kristina Berg Lorvik; Bjarne Bogen; Alexandre Corthay
Journal:  Blood       Date:  2012-03-01       Impact factor: 22.113

2.  MHC class II-restricted presentation of intracellular antigen.

Authors:  S Weiss; B Bogen
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

3.  Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens.

Authors:  Anders Aune Tveita; Fredrik Schjesvold; Ole Audun Haabeth; Marte Fauskanger; Bjarne Bogen
Journal:  Cancer Res       Date:  2015-06-02       Impact factor: 12.701

4.  T helper cell recognition of idiotopes on lambda 2 light chains of M315 and T952: evidence for dependence on somatic mutations in the third hypervariable region.

Authors:  B Bogen; T Jørgensen; K Hannestad
Journal:  Eur J Immunol       Date:  1985-03       Impact factor: 5.532

5.  Indirect CD4+ T-cell-mediated elimination of MHC II(NEG) tumor cells is spatially restricted and fails to prevent escape of antigen-negative cells.

Authors:  Anders A Tveita; Fredrik H Schjesvold; Olav Sundnes; Ole Audun W Haabeth; Guttorm Haraldsen; Bjarne Bogen
Journal:  Eur J Immunol       Date:  2014-06-20       Impact factor: 5.532

6.  M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells.

Authors:  Moniek Heusinkveld; Peggy J de Vos van Steenwijk; Renske Goedemans; Tamara H Ramwadhdoebe; Arko Gorter; Marij J P Welters; Thorbald van Hall; Sjoerd H van der Burg
Journal:  J Immunol       Date:  2011-06-27       Impact factor: 5.422

7.  CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells.

Authors:  Z Qin; T Blankenstein
Journal:  Immunity       Date:  2000-06       Impact factor: 31.745

8.  CD4+ T-cell-Mediated Rejection of MHC Class II-Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs.

Authors:  Ole Audun W Haabeth; Marte Fauskanger; Melanie Manzke; Bjarne Bogen; Anders A Tveita; Katrin U Lundin; Alexandre Corthay
Journal:  Cancer Res       Date:  2018-05-11       Impact factor: 12.701

9.  An immunogenic personal neoantigen vaccine for patients with melanoma.

Authors:  Patrick A Ott; Zhuting Hu; Derin B Keskin; Sachet A Shukla; Jing Sun; David J Bozym; Wandi Zhang; Adrienne Luoma; Anita Giobbie-Hurder; Lauren Peter; Christina Chen; Oriol Olive; Todd A Carter; Shuqiang Li; David J Lieb; Thomas Eisenhaure; Evisa Gjini; Jonathan Stevens; William J Lane; Indu Javeri; Kaliappanadar Nellaiappan; Andres M Salazar; Heather Daley; Michael Seaman; Elizabeth I Buchbinder; Charles H Yoon; Maegan Harden; Niall Lennon; Stacey Gabriel; Scott J Rodig; Dan H Barouch; Jon C Aster; Gad Getz; Kai Wucherpfennig; Donna Neuberg; Jerome Ritz; Eric S Lander; Edward F Fritsch; Nir Hacohen; Catherine J Wu
Journal:  Nature       Date:  2017-07-05       Impact factor: 49.962

10.  Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer.

Authors:  Ole Audun Werner Haabeth; Kristina Berg Lorvik; Clara Hammarström; Ian M Donaldson; Guttorm Haraldsen; Bjarne Bogen; Alexandre Corthay
Journal:  Nat Commun       Date:  2011       Impact factor: 14.919

View more
  10 in total

Review 1.  Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved.

Authors:  Edward F Fritsch; Ute E Burkhardt; Nir Hacohen; Catherine J Wu
Journal:  Cancer Immunol Res       Date:  2020-12       Impact factor: 11.151

2.  Identification of Immune-Related Genes for Risk Stratification in Multiple Myeloma Based on Whole Bone Marrow Gene Expression Profiling.

Authors:  Qiang-Sheng Wang; Qi-Qin Shi; Ye Meng; Meng-Ping Chen; Jian Hou
Journal:  Front Genet       Date:  2022-05-26       Impact factor: 4.772

3.  Induction of Therapeutic Protection in an HPV16-Associated Mouse Tumor Model Through Targeting the Human Papillomavirus-16 E5 Protein to Dendritic Cells.

Authors:  Oscar Badillo-Godinez; Adolfo Pedroza-Saavedra; Veronica Valverde-Garduño; Victor Bermudez-Morales; Minerva Maldonado-Gama; Ricardo Leon-Letelier; Laura C Bonifaz; Fernando Esquivel-Guadarrama; Lourdes Gutierrez-Xicotencatl
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

Review 4.  The role of CD4 T cells in rejection of solid tumors.

Authors:  Lucia Poncette; Julia Bluhm; Thomas Blankenstein
Journal:  Curr Opin Immunol       Date:  2021-10-04       Impact factor: 7.486

5.  Cellular Interaction Analysis Characterizing Immunosuppressive Microenvironment Functions in MM Tumorigenesis From Precursor Stages.

Authors:  Zhenhao Liu; Siwen Zhang; Hong Li; Jiaojiao Guo; Dan Wu; Wen Zhou; Lu Xie
Journal:  Front Genet       Date:  2022-03-23       Impact factor: 4.599

6.  PAD-2-mediated citrullination of nucleophosmin provides an effective target for tumor immunotherapy.

Authors:  Ruhul H Choudhury; Peter Symonds; Samantha J Paston; Ian Daniels; Katherine W Cook; Mohamed Gijon; Rachael L Metheringham; Victoria A Brentville; Lindy G Durrant
Journal:  J Immunother Cancer       Date:  2022-02       Impact factor: 13.751

7.  An emerging prognosis prediction model for multiple myeloma: Hypoxia-immune related microenvironmental gene signature.

Authors:  Zhengyu Yu; Bingquan Qiu; Linfeng Li; Jing Xu; Hui Zhou; Ting Niu
Journal:  Front Oncol       Date:  2022-08-30       Impact factor: 5.738

8.  Construction of a Prognosis Model of the Pyroptosis-Related Gene in Multiple Myeloma and Screening of Core Genes.

Authors:  Can Li; Hongzheng Liang; Sicheng Bian; Xiaoxu Hou; Yanping Ma
Journal:  ACS Omega       Date:  2022-09-15

Review 9.  Roles of CD4+ T cells as mediators of antitumor immunity.

Authors:  Dmitriy S Kravtsov; Amy K Erbe; Paul M Sondel; Alexander L Rakhmilevich
Journal:  Front Immunol       Date:  2022-09-09       Impact factor: 8.786

Review 10.  Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.

Authors:  Michael Pisano; Yan Cheng; Fumou Sun; Binod Dhakal; Anita D'Souza; Saurabh Chhabra; Jennifer M Knight; Sridhar Rao; Fenghuang Zhan; Parameswaran Hari; Siegfried Janz
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.